ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Duration-dependent effects of adjuvant imatinib on recurrence-free and overall survival after resection of gastrointestinal stromal tumors: a systematic review and meta-analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant imatinib is the standard postoperative treatment for patients with intermediate- and high-risk gastrointestinal stromal tumors (GISTs). However, uncertainty remains regarding the optimal duration of therapy and its long-term effects on recurrence-free survival (RFS) and overall survival (OS). This study aimed to evaluate the efficacy and safety of adjuvant imatinib following complete surgical resection of GISTs and to assess the influence of treatment duration on clinical outcomes.
methodsA systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Scopus, and the Cochrane Library were searched from inception to March 2025. Studies evaluating adjuvant imatinib after complete GIST resection were included. The primary outcome was recurrence-based survival (RFS/DFS/RFI), while secondary outcomes included OS and treatment-related adverse events. Randomized and non-randomized studies were synthesized, and pooled hazard ratios (HRs) were calculated using random-effects models.
resultsSixteen studies involving 3531 patients met the inclusion criteria, and eight studies provided data suitable for quantitative synthesis. Adjuvant imatinib significantly reduced the risk of recurrence or death compared with surgery alone (pooled HR = 0.49, 95% CI: 0.35-0.67). Substantial heterogeneity was observed (I
conclusionsAdjuvant imatinib significantly improves recurrence-free survival in patients with resected intermediate- and high-risk GISTs. Treatment durations of at least three years provide greater recurrence prevention than shorter regimens. Although overall survival benefits remain less certain, the therapy demonstrates a favorable safety profile. Extended treatment beyond three years appears promising but requires further investigation in adequately powered prospective studies.
Indexed as
Identifiers
42295647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.